Barriers and outcomes: TB patients co-infected with HIV accessing antiretroviral therapy in rural Zambia

被引:38
|
作者
Chileshe, Muatale [1 ,2 ]
Bond, Virginia Anne [1 ,3 ]
机构
[1] ZAMBART Project, Sch Med, Lusaka, Zambia
[2] Univ Cape Town, ZA-7925 Cape Town, South Africa
[3] LSHTM, Hlth Policy Unit, Fac Publ Hlth & Policy, London WC1E 7HT, England
来源
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2010年 / 22卷
关键词
TB; HIV; Zambia; ART; food security; RESOURCE-POOR SETTINGS; ADHERENCE; TANZANIA; PROGRAM; KISESA;
D O I
10.1080/09540121003617372
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The vulnerabilities that underlie barriers faced by the rural poor whilst trying to access and adhere to "free'' antiretroviral treatment (ART) demand more attention. This paper highlights barriers that poor rural Zambians co-infected with tuberculosis (TB) and HIV and their households faced in accessing ART between September 2006 and July 2007, and accounts for patient outcomes by the end of TB treatment and (more sporadically) beyond October 2009. The analysis draws on findings from wider anthropological fieldwork on the converging impact of TB, HIV and food insecurity, focusing for the purpose of this paper on ethnographic case-studies of seven newly diagnosed TB patients co-infected with HIV and their six households (one household had two TB patients). Economic barriers included being pushed into deeper poverty by managing TB, rural location, absence of any external assistance, and mustering time and extended funds for transport and "special food'' during and beyond the end of TB. In the case of death, funeral costs were astronomical. Social barriers included translocation, broken marriages, a sub-ordinate household position, gender relations, denial, TB/HIV stigma and the difficulty of disclosure. Health facility barriers involved understaffing, many steps, lengthy procedures and inefficiencies (lost blood samples, electricity cuts). By the end of TB treatment, outcomes were mixed; two co-infected patients had died, three had started ART and two had yet to start ART. The three on ART underwent a striking transformation in the short term. By October 2009, two more had died and three were doing well. The study advocates nutritional support and other material support (especially transport funds) for co-infected TB patients until ART is accessed and livelihood regained. More prompt diagnosis of TB and reducing steps and increasing the reach of the ART programme in rural areas are also recommended.
引用
收藏
页码:51 / 59
页数:9
相关论文
共 50 条
  • [21] Impact of Highly Active Antiretroviral Therapy on Hepatitis C Virus Protease Quasispecies Diversity in HIV Co-Infected Patients
    Winters, Mark A.
    Chary, Aarthi
    Eison, Robert
    Asmuth, David
    Holodniy, Mark
    JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (05) : 791 - 798
  • [22] Association of vitamin D with HIV infected individuals, TB infected individuals, and HIV-TB co-infected individuals: a systematic review and meta-analysis
    Xie, Kaidi
    Zhang, Yang
    Zhang, Mei
    Wu, Hao
    Zheng, Luyao
    Ji, Jiahao
    Li, Zhen
    Wang, Wen
    Zhang, Tong
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [23] Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients
    Plaza, Zulema
    Soriano, Vincent
    del Mar Gonzalez, Maria
    Di Lello, Federico A.
    Macias, Juan
    Labarga, Pablo
    Antonio Pineda, Juan
    Poveda, Eva
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (12) : 2838 - 2842
  • [24] Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India
    Isaakidis, Petros
    Varghese, Bhanumati
    Mansoor, Homa
    Cox, Helen S.
    Ladomirska, Joanna
    Saranchuk, Peter
    Da Silva, Esdras
    Khan, Samsuddin
    Paryani, Roma
    Udwadia, Zarir
    Migliori, Giovanni Battista
    Sotgiu, Giovanni
    Reid, Tony
    PLOS ONE, 2012, 7 (07):
  • [25] Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients
    Tural, C
    Fuster, D
    Tor, J
    Ojanguren, I
    Sirera, G
    Ballesteros, A
    Lasanta, JAJ
    Planas, R
    Rey-Joly, C
    Clotet, B
    JOURNAL OF VIRAL HEPATITIS, 2003, 10 (02) : 118 - 125
  • [26] Impact of HBeAg status on immune recovery in HIV/HBV co-infected patients after highly active antiretroviral therapy
    Nie, Yuan
    Deng, XiZi
    Lan, Yun
    Li, Linghua
    Cai, Weiping
    Li, Feng
    Hu, FengYu
    INFECTION GENETICS AND EVOLUTION, 2021, 91
  • [27] Survival rate and predictors of mortality among TB/HIV co-infected adult patients: retrospective cohort study
    Lelisho, Mesfin Esayas
    Wotale, Teramaj Wongel
    Tareke, Seid Ali
    Alemu, Bizuwork Derebew
    Hassen, Sali Suleman
    Yemane, Daniel Melese
    Korsa, Birhanu Bedada
    Bedaso, Namso Geda
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [28] A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa
    Shoko, C.
    Chikobvu, D.
    Bessong, P. O.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2020, 110 (04): : 313 - 319
  • [29] The influence of partnership on contraceptive use among HIV-infected women accessing antiretroviral therapy in rural Uganda
    Nieves, Christina I.
    Kaida, Angela
    Seage, George R., III
    Kabakyenga, Jerome
    Muyindike, Winnie
    Boum, Yap
    Mocello, A. Rain
    Martin, Jeffrey N.
    Hunt, Peter W.
    Haberer, Jessica E.
    Bangsbereg, David R.
    Mafthews, Lynn T.
    CONTRACEPTION, 2015, 92 (02) : 152 - 159
  • [30] Tuberculosis treatment default among HIV-TB co-infected patients in urban Uganda
    Elbireer, Sawsan
    Guwatudde, David
    Mudiope, Peter
    Nabbuye-Sekandi, Juliet
    Manabe, Yukari C.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2011, 16 (08) : 981 - 987